Examining relationship between IOP, sleep patterns using contact lens sensor
August 26th 2014IOP patterns derived from measurements obtained with a non-invasive contact lens sensor (CLS; Triggerfish, Sensimed AG) correlate well with polysomnographic recordings of rapid eye movement (REM) sleep, according to research presented by Kaweh Mansouri, MD, and Tarek Shaarawy, MD.
Eye donation by gay teen that committed suicide rejected
August 23rd 2014A gay teen that committed suicide after being bullied by his classmates had one last wish-to donate his organs. While his kidneys, liver, heart, and lungs were donated, because of an FDA regulation, his eyes were not due to his sexual orientation.
Intracameral antibiotics a must to avoid infection post-cataract surgery
August 19th 2014The creation of a sufficiently long-internal incision as well as stromal hydration and a moderate final IOP are effective steps to reduce fluid ingress-and lower risk of infection-into the eye following cataract surgery, according to Neal Shorstein, MD.
AAO aims to raise Acanthamoeba keratitis awareness
August 19th 2014In an attempt to combat the risk of eye infections in contact lens wearers, the American Academy of Ophthalmology (AAO) has joined up with the FDA, the Contact Lens Association of Ophthalmologists, the American Academy of Optometry, and the American Optometric Association.
AMA wants Sunshine Act database publication delayed
August 19th 2014The American Medical Association (AMA) has asked the Centers for Medicare and Medicaid Services (CMS) to lengthen the timeframe for registering and using the Open Payments system. This would allow physicians enough time to review and seek corrections of inaccurate claims made by pharmaceutical companies, device manufacturers, and group purchasing organizations under the Sunshine Act, the AMS noted.
Why immunomodulation is the next logical step in glaucoma control
August 12th 2014Research in glaucoma that evaluates the molecular interactions between resident and systemic immune cells and neurons is progressing with the goal of providing translational applications for immunomodulation as a neuroprotective strategy in patients with glaucoma, said Gülgün Tezel, MD.
Alcon IOP-lowering glaucoma treatment approved in EU
August 5th 2014Alcon Laboratories’ brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL (Simbrinza) eye drop formulation have been approved by the European Commission to decrease elevated IOP in adult patients with open-angle glaucoma or ocular hypertension.
Iluvien for chronic DME approved for marketing in Denmark, Norway
August 5th 2014The Danish Health and Medicines Authority, along with the Norwegian Medicines Evaluation Board, have granted marketing authorization to Alimera Sciences’ Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) in their respective countries.
Turning optical shoppers into buyers: The power of the demonstration
August 1st 2014In the demonstration, the optician recommends and demonstrates eyewear products that will enhance the customer's visual lifestyle and appearance. The customer is educated and has the opportunity, whenever possible, of experiencing the recommended product.
Fixed dose of ROCK/NET inhibitor, latanoprost meets endpoint
August 1st 2014A fixed-dose combination containing an investigational rho kinase/norepinephrine transporter inhibitor and latanoprost 0.005% achieved its primary endpoint, showing potential as a high-efficacy, IOP-lowering therapy in a phase IIb trial.
Aflibercept for DME effective therapy in VISTA, VIVID trials
August 1st 2014Data from the phase III VISTA-DME trial show aflibercept 2 mg every 4 or every 8 weeks remains superior to laser photocoagulation and is associated with stable improvements in best-corrected visual acuity and macular thickness.